Lilly-Lupin link revs up Indian diabetes
This article was originally published in Scrip
A string of new marketing deals is set to redefine competition in the growing Indian diabetes market. The latest alliance involves Lilly and Lupin, where the Indian firm will promote and distribute Lilly's Huminsulin range in India and Nepal, doubling doctor reach for the insulin products to about 45,000 almost overnight.
You may also be interested in...
India has seen an uptick in in-licensing deals, with robust growth in the number of novel drugs in such arrangements delivering gains for both the domestic partner and innovator company.
In-licensing and co-marketing/co-promotion deals are on the up in India, as local and foreign companies tango together to reach more patients and expand their business in the country's competitive market. Lupin-Boehringer, Dr Reddy’s-UCB and Glenmark-Helsinn are among the recent companies doing deals in the area.
Eli Lilly and Lupin are building on their alliance in India, with Lupin introducing Lilly’s Cialis (tadalafil) – a teeming market awaits the product, however.